Abiomed Inc (ABMD.O) Quote| Reuters.com
Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

106.80USD
10:11am EDT
Change (% chg)

$1.71 (+1.63%)
Prev Close
$105.09
Open
$105.98
Day's High
$106.81
Day's Low
$105.66
Volume
100,393
Avg. Vol
632,631
52-wk High
$110.68
52-wk Low
$64.03

ABMD.O

Chart for ABMD.O

About

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company's products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologi... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $4,491.04
Shares Outstanding(Mil.): 42.74
Dividend: --
Yield (%): --

Financials

  ABMD.O Industry Sector
P/E (TTM): 123.64 31.02 34.69
EPS (TTM): 0.85 -- --
ROI: 11.28 8.50 14.13
ROE: 11.55 12.81 15.35

BRIEF-Abiomed reports Q4 GAAP earnings per share $0.24

* Abiomed announces Q4 FY 2016 revenue of $94.0 million, up 39% over prior year

May 03 2016

BRIEF-Abiomed posts Q4 earnings per share $0.24

* Abiomed announces Q4 FY 2016 revenue of $94.0 million, up 39 pct over prior year

May 03 2016

FDA approves Abiomed's device to treat cardiac shocks

The U.S Food and Drug Administration approved Abiomed Inc's heart pump to treat patients who suffer cardiac shock after heart attack or heart surgery, sending its shares up about 4 percent in extended trading.

Apr 07 2016

FDA approves Abiomed's device to treat cardiac shocks

April 7 The U.S Food and Drug Administration approved Abiomed Inc's heart pump to treat patients who suffer cardiac shock after heart attack or heart surgery, sending its shares up about 4 percent in extended trading.

Apr 07 2016

BRIEF-Abiomed Impella therapy receives FDA approval

* Abiomed impella therapy receives fda approval for cardiogenic shock after heart attack or heart surgery

Apr 07 2016

BRIEF-Abiomed does not anticipate FDA advisory panel prior to PMA approval

* Co, FDA agreed on indication for use for pre-market approval ('PMA') for Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices

Mar 21 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.